Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
November 2017—Roche announced the expanded use of the Ventana PD-L1 (SP142) Assay in non-small cell lung cancer and metastatic urothelial carcinoma in CE markets in which the Roche cancer immunotherapy medicine Tecentriq is approved.
November 2017—IntegraGen announced the CE-IVD marking and commercial launch of its miRpredX 31-3p test kit in the European Union.
November 2017—Blood Systems Research Institute announced a collaboration with Hologic to more precisely and efficiently measure the human immunodeficiency virus latent reservoir in clinical samples using Hologic’s Panther system.
November 2017—Royal Philips announced that two pathology laboratories in Austria have made the transition to a fully digital workflow. The Pathology Institute in Hall and the Pathology Institute at Tirol Kliniken Innsbruck have fully digitized their diagnostic process with Philips IntelliSite Pathology Solution, a whole slide imaging system for primary diagnosis.
November 2017—Vector Laboratories introduced the VectaFluor Duet kit, offering ready-to-use immunofluorescence double labeling. This kit is ideal for use on a range of frozen and formalin-fixed, paraffin-embedded tissue samples, combining primary and secondary antibodies to streamline workflow.
November 2017—Tetracore announced that its T-Cor 8 portable real-time PCR thermocycler has achieved CE-IVD status. The T-Cor 8, and its proprietary software, is a point-of-care diagnostic system that enables real-time molecular testing in hospitals, clinics, physician offices, and field applications.
November 2017—The Clinical and Laboratory Standards Institute has published “Developing and Managing a Medical Laboratory (Test) Utilization Program (GP49),” which provides guidance on the process for developing and effectively maintaining a test utilization or laboratory stewardship committee.
November 2017—Beckman Coulter Life Sciences has introduced DuraClone RE antibody panels for the detection of rare, abnormal events in blood disorders. The panels provide tools to study low frequency populations of abnormal CD5+ B cells (RE CLB), abnormal plasma cells (RE PC), or abnormal B progenitor cells (RE ALB).
November 2017—Mologic (Thurleigh, U.K.) received CE marking for its BVPro, a 15-minute point-of-care diagnostic that detects sialidase enzyme activity from a vaginal swab sample.
November 2017—iBio has partnered with TheoremDx to develop proteins for rapid diagnostic testing products. The collaboration will leverage the TheoremDx point-of-care diagnostic system and the protein development and manufacturing capabilities
